TheraRadar
← Back
Data updated: Jul 17, 2026

LIAONING CHENGDA

Generics

LIAONING CHENGDA is a generic drug manufacturer focused on Infectious Disease.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

LIAONING CHENGDA's Key Drugs

LIAONING CHENGDA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

LIAONING CHENGDA's Recent FDA Approvals

New NDA/BLA approvals for LIAONING CHENGDA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

LIAONING CHENGDA's Therapeutic Areas

LIAONING CHENGDA's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Infectious Disease 100%
0 drugs Phase 1: 1

LIAONING CHENGDA's Top Competitors

LIAONING CHENGDA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

LIAONING CHENGDA Pipeline Snapshot

LIAONING CHENGDA has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 0 Phase 2 and 1 Phase 1.

0
Phase 3
0
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Infectious Disease pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling